EULAV Asset Management Decreases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

EULAV Asset Management lowered its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 44.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 27,015 shares of the medical device company's stock after selling 21,985 shares during the period. EULAV Asset Management's holdings in DexCom were worth $1,845,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in DXCM. Brighton Jones LLC lifted its holdings in shares of DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Bank Pictet & Cie Europe AG increased its position in shares of DexCom by 1.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock valued at $8,637,000 after acquiring an additional 2,010 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of DexCom by 43.2% during the fourth quarter. Jones Financial Companies Lllp now owns 10,916 shares of the medical device company's stock valued at $849,000 after acquiring an additional 3,291 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $49,000. Finally, Atria Investments Inc increased its position in shares of DexCom by 13.4% during the fourth quarter. Atria Investments Inc now owns 17,379 shares of the medical device company's stock valued at $1,352,000 after acquiring an additional 2,059 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on DXCM. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Piper Sandler decreased their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Citigroup reaffirmed a "buy" rating and set a $102.00 price target (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Truist Financial began coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Finally, Wall Street Zen downgraded DexCom from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Five investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and an average target price of $98.50.

DexCom Stock Performance

Shares of DexCom stock traded up $0.01 during trading hours on Monday, reaching $82.94. The company had a trading volume of 2,782,214 shares, compared to its average volume of 4,406,698. DexCom, Inc. has a one year low of $57.52 and a one year high of $117.19. The business has a fifty day simple moving average of $83.26 and a 200 day simple moving average of $79.85. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The firm has a market cap of $32.52 billion, a PE ratio of 61.90, a price-to-earnings-growth ratio of 1.77 and a beta of 1.44.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the business earned $0.32 earnings per share. DexCom's revenue was up 12.5% on a year-over-year basis. On average, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the sale, the director owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction on Thursday, June 26th. The shares were sold at an average price of $85.06, for a total value of $124,697.96. Following the sale, the executive vice president directly owned 108,155 shares of the company's stock, valued at $9,199,664.30. This represents a 1.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,190 shares of company stock worth $2,281,732 over the last three months. Corporate insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.